Crew Capital Management Ltd. Trims Stock Position in Eli Lilly and Company (NYSE:LLY)

Crew Capital Management Ltd. lowered its stake in Eli Lilly and Company (NYSE:LLY) by 0.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 9,138 shares of the company’s stock after selling 83 shares during the quarter. Eli Lilly and Company makes up approximately 5.4% of Crew Capital Management Ltd.’s investment portfolio, making the stock its 5th largest position. Crew Capital Management Ltd.’s holdings in Eli Lilly and Company were worth $5,327,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. FARMERS & MERCHANTS TRUST Co OF LONG BEACH raised its position in Eli Lilly and Company by 5.1% during the 3rd quarter. FARMERS & MERCHANTS TRUST Co OF LONG BEACH now owns 3,514 shares of the company’s stock worth $1,887,000 after purchasing an additional 170 shares during the last quarter. Lantz Financial LLC boosted its stake in Eli Lilly and Company by 9.8% during the 3rd quarter. Lantz Financial LLC now owns 1,219 shares of the company’s stock valued at $655,000 after purchasing an additional 109 shares during the last quarter. Covenant Partners LLC boosted its stake in Eli Lilly and Company by 101.4% during the 3rd quarter. Covenant Partners LLC now owns 1,003 shares of the company’s stock valued at $539,000 after purchasing an additional 505 shares during the last quarter. Bfsg LLC purchased a new position in shares of Eli Lilly and Company in the 3rd quarter worth approximately $564,000. Finally, Lake Street Financial LLC raised its holdings in shares of Eli Lilly and Company by 1.9% in the 3rd quarter. Lake Street Financial LLC now owns 7,740 shares of the company’s stock worth $4,214,000 after purchasing an additional 147 shares during the period. Institutional investors and hedge funds own 82.53% of the company’s stock.

Insider Activity at Eli Lilly and Company

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 78,573 shares of the firm’s stock in a transaction on Wednesday, January 31st. The shares were sold at an average price of $648.07, for a total value of $50,920,804.11. Following the sale, the insider now directly owns 99,333,810 shares in the company, valued at approximately $64,375,262,246.70. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 0.13% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several analysts have weighed in on the company. Erste Group Bank raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Wednesday, April 3rd. BMO Capital Markets boosted their target price on Eli Lilly and Company from $710.00 to $865.00 and gave the stock an “outperform” rating in a report on Wednesday, February 7th. Citigroup upped their price target on Eli Lilly and Company from $675.00 to $895.00 and gave the company a “buy” rating in a report on Tuesday, April 2nd. TheStreet upgraded Eli Lilly and Company from a “c+” rating to a “b” rating in a research report on Friday, March 8th. Finally, Barclays upped their price objective on Eli Lilly and Company from $680.00 to $810.00 and gave the company an “overweight” rating in a research report on Wednesday, February 7th. Three research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $728.05.

Eli Lilly and Company Stock Performance

LLY traded up $3.69 on Monday, hitting $737.20. 2,724,106 shares of the company’s stock were exchanged, compared to its average volume of 3,017,765. The stock has a fifty day moving average of $761.79 and a two-hundred day moving average of $667.10. Eli Lilly and Company has a twelve month low of $392.26 and a twelve month high of $800.78. The firm has a market cap of $700.46 billion, a PE ratio of 126.34, a P/E/G ratio of 1.60 and a beta of 0.34. The company has a current ratio of 0.94, a quick ratio of 0.73 and a debt-to-equity ratio of 1.69.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Tuesday, February 6th. The company reported $2.49 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.30 by $0.19. The business had revenue of $9.35 billion during the quarter, compared to analysts’ expectations of $8.95 billion. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The business’s revenue was up 28.1% on a year-over-year basis. During the same period last year, the firm posted $2.09 earnings per share. On average, research analysts anticipate that Eli Lilly and Company will post 12.51 earnings per share for the current fiscal year.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.